What the US Sunshine Act Taught Us About HCP Interactions— And What Italian Companies Should Learn
Author
Ned Mumtaz is an international transparency reporting expert with extensive experience producing accurate and compliant transparency reports for over 150 pharmaceutical companies globally.
He has held leadership positions at Pfizer and Otsuka, distinguishing himself by ensuring high standards of accuracy, reliability, and regulatory compliance in reporting processes. He is recognized in the industry for his contributions to the development of global transparency models and for promoting operational best practices in compliance.
Cerchi supporto per la compliance al Sunshine Act?
Hai domande pratiche?
Dai un’occhiata alla nostra sezione Domande Frequenti per risposte chiare su scadenze, obblighi e strategie.
When the US Open Payments database went live and a surgeon in Ohio Googled his own name for the first time, he found $47,000 in disclosed payments from a device manufacturer. He had no idea the figure was that high. He also had no idea it was public. He called his hospital’s legal team before he called the company. This is not an unusual story. (Citation Required)
Across the United States, the launch of mandatory HCP transparency reporting through the Open Payments program produced a wave of confused, anxious, and occasionally furious phone calls from healthcare professionals who felt they had been disclosed without warning. Relationships that had taken years to build were strained in a single afternoon. Compliance teams that had spent months getting their data right had spent almost no time preparing the people whose data they were reporting.
Italy is poised to repeat this mistake, unless manufacturers decide, now, that HCP interactions are as much a part of Italian Sunshine Act readiness as data management and XML generation.
The Italian HCP’s Starting Point
Most Italian HCPs are aware, in a general sense, that transparency legislation is coming. What they don’t know are the specifics: which payments will be disclosed, where the information will be published, for how long it will be accessible, or why a life science company, their longstanding industry contact, suddenly needs their fiscal code and date of birth.
That last point is where most early friction will occur. For years, companies have engaged Italian HCPs for consultancies, advisory boards, speaker fees, and congress attendance without systematically collecting the personal identifiers that Italian Sunshine Act reporting requires. The first time a medical science liaison or a sales representative asks a senior surgeon for their fiscal code and confirms their date of birth, the surgeon’s reaction will depend almost entirely on whether they understood, in advance, why this information is needed and what will be done with it.
Why Manufacturers Should Lead the Conversation
The temptation is to wait for the industry to communicate collectively, for associations, for the Ministry of Health, to run a campaign. This will happen. It will also happen late, reach imperfectly, and land with considerably less trust than a direct conversation from a company the HCP already works with.
Manufacturers who brief their HCPs early, explaining clearly what the law requires, what data will be collected, how it will be protected under GDPR, and where it will be published, will have a meaningfully smoother data collection process. They will also be better positioned when HCPs receive their first notification that their payments have been disclosed. “We told you this was coming” is a far better response than silence.
What Good Healthcare Interactions Look Like in Practice
The most effective approach is layered. At the broadest level, a dedicated page on the company’s website, in Italian, clearly written, covering the most common questions, gives HCPs somewhere to go when they have questions and signals that the company takes its transparency obligations seriously. This page should explain what will be disclosed, where, how to verify or challenge the data, and who to contact with concerns.
At the relationship level, medical science liaisons and field teams need to be trained to discuss the Italian Sunshine Act conversationally, not to read from a script, but to be able to answer questions confidently when they come up during an engagement visit. The question “why do you need my fiscal code?” should never produce an awkward pause.
For high-value relationships such as with key opinion leaders, research collaborators, advisory board members, a direct personal briefing is worth the investment. These are the HCPs most likely to scrutinise the disclosed data closely, most likely to discuss it publicly, and most influential in shaping how the broader HCP community perceives a company’s transparency practices.
The Italian Sunshine Act will be a defining moment for industry-HCP relationships in Italy. The companies that manage that moment, rather than letting it manage them, will find that transparency, handled well, strengthens trust rather than undermining it. The ones that don’t will be having very different conversations in the year that follows.
Assess your organisation’s preparedness for Italian Sunshine Reporting
Whether you are preparing for your first disclosure or looking to streamline an existing process, getting ongoing expert advice and choosing the right transparency reporting partner can help you map your data landscape, close compliance gaps, and generate Ministry-compliant XML files with confidence.
→ Attend our upcoming Italian Sunshine Reporting events, online or in person to work directly with us and learn to build structured, audit-ready Italian Sunshine transparency processes.
→ Get expert advice tailored to your situation by asking specific questions, whether that’s about retroactive data, field team workflows, or cross-border engagements.
→ Not sure where to start? Explore our resources and blogs to understand what Italian Sunshine Reporting means specifically for your organisation.
When the US Open Payments database went live and a surgeon in Ohio Googled his own name for the first time, he found $47,000 in disclosed payments from a device manufacturer. He had no idea the figure was that high. He also had no idea it was public. He called his hospital’s legal team before he called the company. This is not an unusual story. (Citation Required)
Across the United States, the launch of mandatory HCP transparency reporting through the Open Payments program produced a wave of confused, anxious, and occasionally furious phone calls from healthcare professionals who felt they had been disclosed without warning. Relationships that had taken years to build were strained in a single afternoon. Compliance teams that had spent months getting their data right had spent almost no time preparing the people whose data they were reporting.
Italy is poised to repeat this mistake, unless manufacturers decide, now, that HCP interactions are as much a part of Italian Sunshine Act readiness as data management and XML generation.
The Italian HCP’s Starting Point
Most Italian HCPs are aware, in a general sense, that transparency legislation is coming. What they don’t know are the specifics: which payments will be disclosed, where the information will be published, for how long it will be accessible, or why a life science company, their longstanding industry contact, suddenly needs their fiscal code and date of birth.
That last point is where most early friction will occur. For years, companies have engaged Italian HCPs for consultancies, advisory boards, speaker fees, and congress attendance without systematically collecting the personal identifiers that Italian Sunshine Act reporting requires. The first time a medical science liaison or a sales representative asks a senior surgeon for their fiscal code and confirms their date of birth, the surgeon’s reaction will depend almost entirely on whether they understood, in advance, why this information is needed and what will be done with it.
Why Manufacturers Should Lead the Conversation
The temptation is to wait for the industry to communicate collectively, for associations, for the Ministry of Health, to run a campaign. This will happen. It will also happen late, reach imperfectly, and land with considerably less trust than a direct conversation from a company the HCP already works with.
Manufacturers who brief their HCPs early, explaining clearly what the law requires, what data will be collected, how it will be protected under GDPR, and where it will be published, will have a meaningfully smoother data collection process. They will also be better positioned when HCPs receive their first notification that their payments have been disclosed. “We told you this was coming” is a far better response than silence.
What Good Healthcare Interactions Look Like in Practice
The most effective approach is layered. At the broadest level, a dedicated page on the company’s website, in Italian, clearly written, covering the most common questions, gives HCPs somewhere to go when they have questions and signals that the company takes its transparency obligations seriously. This page should explain what will be disclosed, where, how to verify or challenge the data, and who to contact with concerns.
At the relationship level, medical science liaisons and field teams need to be trained to discuss the Italian Sunshine Act conversationally, not to read from a script, but to be able to answer questions confidently when they come up during an engagement visit. The question “why do you need my fiscal code?” should never produce an awkward pause.
For high-value relationships such as with key opinion leaders, research collaborators, advisory board members, a direct personal briefing is worth the investment. These are the HCPs most likely to scrutinise the disclosed data closely, most likely to discuss it publicly, and most influential in shaping how the broader HCP community perceives a company’s transparency practices.
The Italian Sunshine Act will be a defining moment for industry-HCP relationships in Italy. The companies that manage that moment, rather than letting it manage them, will find that transparency, handled well, strengthens trust rather than undermining it. The ones that don’t will be having very different conversations in the year that follows.
Assess your organisation’s preparedness for Italian Sunshine Reporting
Whether you are preparing for your first disclosure or looking to streamline an existing process, getting ongoing expert advice and choosing the right transparency reporting partner can help you map your data landscape, close compliance gaps, and generate Ministry-compliant XML files with confidence.
→ Attend our upcoming Italian Sunshine Reporting events, online or in person to work directly with us and learn to build structured, audit-ready Italian Sunshine transparency processes.
→ Get expert advice tailored to your situation by asking specific questions, whether that’s about retroactive data, field team workflows, or cross-border engagements.
→ Not sure where to start? Explore our resources and blogs to understand what Italian Sunshine Reporting means specifically for your organisation.
Author
Ned Mumtaz is an international transparency reporting expert with extensive experience producing accurate and compliant transparency reports for over 150 pharmaceutical companies globally.
He has held leadership positions at Pfizer and Otsuka, distinguishing himself by ensuring high standards of accuracy, reliability, and regulatory compliance in reporting processes. He is recognized in the industry for his contributions to the development of global transparency models and for promoting operational best practices in compliance.
Recent Blogs
-
Cosa ci ha insegnato il Sunshine Act statunitense sulle interazioni con gli HCP e cosa dovrebbero imparare le aziende italiane
-
Dal dato grezzo al file XML: come dovrebbe funzionare in pratica un processo efficace per il Sunshine Reporting italiano
-
La Sunshine Act italiana è in arrivo: la tua organizzazione è pronta per il transparency reporting?
Cerchi supporto per la compliance al Sunshine Act?
Hai domande pratiche?
Dai un’occhiata alla nostra sezione Domande Frequenti per risposte chiare su scadenze, obblighi e strategie.